- ISIN
- US5015751044
- CUSIP
- 501575104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 21, 2020
Highlights
- Market Cap
- $8.51B
- Enterprise Value
- $8.46B
- EPS (TTM)
- -$3.51
- Total Revenue (TTM)
- $51.47M
- Gross Profit (TTM)
- $17.10M
- EBITDA (TTM)
- -$323.05M
- Year Range
- $36.65 - $130.05
- Target Price
- $117.06
- ROA (TTM)
- -18.88%
- ROE (TTM)
- -20.46%
- Avg. Volume (1M)
- 603K
- Avg. Volume Value (1M)
- $67.79M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KYMR Performance Chart
Kymera Therapeutics, Inc. (KYMR) is up 32.9% since the beginning of the year. At $103 per share, KYMR is trading 20.5% below its 52-week high of $130. Investors who bought $1,000 worth of KYMR shares 5 years ago would now be looking at an investment worth $1,718.
Loading charts...
Compare this symbol against anything
Returns By Period
Kymera Therapeutics, Inc. (KYMR) has returned 32.89% so far this year and 140.69% over the past 12 months.
Kymera Therapeutics, Inc.
- 1D
- -3.37%
- 1M
- -8.91%
- 6M
- 42.25%
- YTD
- 32.89%
- 1Y
- 140.69%
- 3Y*
- 68.33%
- 5Y*
- 11.43%
- 10Y*
- —
- ALL TIME*
- 20.00%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
KYMR Monthly Returns History
Based on dividend-adjusted daily data since Aug 21, 2020, KYMR's average daily return is +0.18%, while the average monthly return is +3.94%. At this rate, an investment would double in approximately 1.5 years.
Historically, 49% of months were positive and 51% were negative. The best month was Nov 2023 with a return of +77.9%, while the worst month was May 2022 at -54.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, KYMR closed higher 49% of trading days. The best single day was Jun 2, 2025 with a return of +45.5%, while the worst single day was May 3, 2022 at -24.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.58% | 25.67% | -8.82% | -2.67% | 0.43% | 40.84% | -9.83% | 32.89% | |||||
| 2025 | -1.59% | -20.81% | -12.70% | 25.21% | -13.51% | 47.23% | 0.25% | -5.83% | 37.38% | 9.26% | 9.77% | 14.63% | 93.41% |
| 2024 | 28.75% | 30.26% | -5.85% | -16.37% | -4.49% | -7.04% | 54.77% | 4.68% | -2.13% | -2.45% | 1.47% | -14.13% | 58.01% |
| 2023 | 49.76% | -16.05% | -5.58% | 6.45% | -6.66% | -21.91% | -4.83% | -12.80% | -27.15% | -16.04% | 77.89% | 22.64% | 2.00% |
| 2022 | -33.85% | -5.33% | 6.44% | -25.92% | -54.48% | 37.98% | 11.88% | 28.33% | -22.99% | 39.37% | -4.48% | -13.87% | -60.69% |
| 2021 | -0.08% | -22.55% | -19.01% | 17.22% | 5.58% | 0.85% | 24.08% | 3.26% | -5.47% | 0.24% | -5.71% | 14.36% | 2.40% |
Benchmark Metrics
Kymera Therapeutics, Inc. has an annualized alpha of 25.55%, beta of 1.55, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since August 21, 2020.
- This stock captured 157.76% of S&P 500 Index gains and 133.77% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 25.55%
- Beta
- 1.55
- R²
- 0.12
- Upside Capture
- 157.76%
- Downside Capture
- 133.77%
Return for Risk
Risk / Return Rank
KYMR ranks 93 for risk / return — above 93% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KYMR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.71 | ||
| Sortino ratioReturn per unit of downside risk | +1.35 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.25 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 4.94 | 2.00 | +2.94 |
| Martin ratioReturn relative to average drawdown | 11.93 | 8.49 | +3.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kymera Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kymera Therapeutics, Inc. was 87.51%, occurring on Oct 27, 2023. Recovery took 529 trading sessions.
The current Kymera Therapeutics, Inc. drawdown is 13.36%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-87.51%Oct 2023 | 2y 10mo | 2y 1mo | 4y 11moDec 2020 - Dec 2025 | — |
-27.74%Jan 2026 | 1mo 12d | 1mo 7d | 2mo 19dDec 2025 - Feb 2026 | — |
-25.43%Sep 2020 | 19d | 1mo | 1mo 19dAug 2020 - Oct 2020 | — |
-24.98%Jun 2026 | 3mo 5d | 20d | 3mo 25dFeb 2026 - Jun 2026 | — |
-13.36%Jul 2026 | 18d | — | 21dJul 2026 - now | — |
Drawdown Indicators
| KYMR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.51% | -56.78% | -30.73% |
Max Drawdown (1Y)Largest decline over 1 year | -27.74% | -9.10% | -18.64% |
Max Drawdown (3Y)Largest decline over 3 years | -59.83% | -18.90% | -40.93% |
Max Drawdown (5Y)Largest decline over 5 years | -83.54% | -25.43% | -58.11% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -13.36% | -1.58% | -11.78% |
Average DrawdownAverage peak-to-trough decline | -48.42% | -10.70% | -37.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.47% | 2.14% | +9.33% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kymera Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kymera Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KYMR relative to other companies in the Biotechnology industry. Currently, KYMR has a P/S ratio of 180.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KYMR in comparison with other companies in the Biotechnology industry. Currently, KYMR has a P/B value of 6.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KYMR
Add Kymera Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KYMR